Cofactor mimics as selective inhibitors of NAD-dependent inosine monophospate dehydrogenase (IMPDH) - The major therapeutic target

Krzysztof W. Pankiewicz, Steven E. Patterson, Paul L. Black, Hiremagalur N. Jayaram, Dipesh Risal, Barry M. Goldstein, Lieven J. Stuyver, Raymond F. Schinazi

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

IMP dehydrogenase, the key enzyme in de novo synthesis of purine nucleotides, is an important therapeutic target. Three inhibitors of IMP dehydrogenase reached the market; ribavirin (Rebetol) a broad-spectrum antiviral agent, which in combination with interferon-α is now used for treatment of hepatitis C virus infections, mizoribine (Bredinin and mycophenolic mofetil (CellCept) have been introduced as immunosuppressants. Numerous novel inhibitors are under development. This review describes recent progress in the development of new drugs based on inhibition of IMP dehydrogenase.

Original languageEnglish (US)
Pages (from-to)887-900
Number of pages14
JournalCurrent Medicinal Chemistry
Volume11
Issue number7
DOIs
StatePublished - Apr 2004
Externally publishedYes

Fingerprint

IMP Dehydrogenase
Inosine
NAD
Oxidoreductases
Ribavirin
Mycophenolic Acid
Purine Nucleotides
Virus Diseases
Immunosuppressive Agents
Viruses
Hepacivirus
Interferons
Antiviral Agents
Therapeutics
Enzymes
Pharmaceutical Preparations
bredinin

ASJC Scopus subject areas

  • Organic Chemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

Pankiewicz, K. W., Patterson, S. E., Black, P. L., Jayaram, H. N., Risal, D., Goldstein, B. M., ... Schinazi, R. F. (2004). Cofactor mimics as selective inhibitors of NAD-dependent inosine monophospate dehydrogenase (IMPDH) - The major therapeutic target. Current Medicinal Chemistry, 11(7), 887-900. https://doi.org/10.2174/0929867043455648

Cofactor mimics as selective inhibitors of NAD-dependent inosine monophospate dehydrogenase (IMPDH) - The major therapeutic target. / Pankiewicz, Krzysztof W.; Patterson, Steven E.; Black, Paul L.; Jayaram, Hiremagalur N.; Risal, Dipesh; Goldstein, Barry M.; Stuyver, Lieven J.; Schinazi, Raymond F.

In: Current Medicinal Chemistry, Vol. 11, No. 7, 04.2004, p. 887-900.

Research output: Contribution to journalArticle

Pankiewicz, KW, Patterson, SE, Black, PL, Jayaram, HN, Risal, D, Goldstein, BM, Stuyver, LJ & Schinazi, RF 2004, 'Cofactor mimics as selective inhibitors of NAD-dependent inosine monophospate dehydrogenase (IMPDH) - The major therapeutic target', Current Medicinal Chemistry, vol. 11, no. 7, pp. 887-900. https://doi.org/10.2174/0929867043455648
Pankiewicz, Krzysztof W. ; Patterson, Steven E. ; Black, Paul L. ; Jayaram, Hiremagalur N. ; Risal, Dipesh ; Goldstein, Barry M. ; Stuyver, Lieven J. ; Schinazi, Raymond F. / Cofactor mimics as selective inhibitors of NAD-dependent inosine monophospate dehydrogenase (IMPDH) - The major therapeutic target. In: Current Medicinal Chemistry. 2004 ; Vol. 11, No. 7. pp. 887-900.
@article{c946722dcbc34871a6f5d15f75a79931,
title = "Cofactor mimics as selective inhibitors of NAD-dependent inosine monophospate dehydrogenase (IMPDH) - The major therapeutic target",
abstract = "IMP dehydrogenase, the key enzyme in de novo synthesis of purine nucleotides, is an important therapeutic target. Three inhibitors of IMP dehydrogenase reached the market; ribavirin (Rebetol) a broad-spectrum antiviral agent, which in combination with interferon-α is now used for treatment of hepatitis C virus infections, mizoribine (Bredinin and mycophenolic mofetil (CellCept) have been introduced as immunosuppressants. Numerous novel inhibitors are under development. This review describes recent progress in the development of new drugs based on inhibition of IMP dehydrogenase.",
author = "Pankiewicz, {Krzysztof W.} and Patterson, {Steven E.} and Black, {Paul L.} and Jayaram, {Hiremagalur N.} and Dipesh Risal and Goldstein, {Barry M.} and Stuyver, {Lieven J.} and Schinazi, {Raymond F.}",
year = "2004",
month = "4",
doi = "10.2174/0929867043455648",
language = "English (US)",
volume = "11",
pages = "887--900",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Cofactor mimics as selective inhibitors of NAD-dependent inosine monophospate dehydrogenase (IMPDH) - The major therapeutic target

AU - Pankiewicz, Krzysztof W.

AU - Patterson, Steven E.

AU - Black, Paul L.

AU - Jayaram, Hiremagalur N.

AU - Risal, Dipesh

AU - Goldstein, Barry M.

AU - Stuyver, Lieven J.

AU - Schinazi, Raymond F.

PY - 2004/4

Y1 - 2004/4

N2 - IMP dehydrogenase, the key enzyme in de novo synthesis of purine nucleotides, is an important therapeutic target. Three inhibitors of IMP dehydrogenase reached the market; ribavirin (Rebetol) a broad-spectrum antiviral agent, which in combination with interferon-α is now used for treatment of hepatitis C virus infections, mizoribine (Bredinin and mycophenolic mofetil (CellCept) have been introduced as immunosuppressants. Numerous novel inhibitors are under development. This review describes recent progress in the development of new drugs based on inhibition of IMP dehydrogenase.

AB - IMP dehydrogenase, the key enzyme in de novo synthesis of purine nucleotides, is an important therapeutic target. Three inhibitors of IMP dehydrogenase reached the market; ribavirin (Rebetol) a broad-spectrum antiviral agent, which in combination with interferon-α is now used for treatment of hepatitis C virus infections, mizoribine (Bredinin and mycophenolic mofetil (CellCept) have been introduced as immunosuppressants. Numerous novel inhibitors are under development. This review describes recent progress in the development of new drugs based on inhibition of IMP dehydrogenase.

UR - http://www.scopus.com/inward/record.url?scp=1842431902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842431902&partnerID=8YFLogxK

U2 - 10.2174/0929867043455648

DO - 10.2174/0929867043455648

M3 - Article

C2 - 15083807

AN - SCOPUS:1842431902

VL - 11

SP - 887

EP - 900

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 7

ER -